title: Virucidal treatment of blood protein products with UVC radiation.
abstract: The virus safety of blood derivatives continues to be of concern, especially with respect to nonenveloped and/or heat-stable viruses. Previously, we demonstrated that treatment of whole plasma, AHF concentrate or fibrinogen with short wavelength ultraviolet light (UVC) results in the inactivation of > or = 10(6) infectious doses (ID) of encephalomyocarditis virus (EMCV), hepatitis A virus (HAV) and porcine parvovirus (PPV), each of which is nonenveloped. Protein recovery was enhanced greatly by inclusion of the flavonoid, rutin, added prior to UVC exposure to quench reactive oxygen species. We now report on the treatment of albumin and intravenous immune globulin (IVIG) isolated by a previously described, integrated chromatographic method. Albumin was treated with either 0.1 or 0.2 J/cm2 UVC in the presence of 0.8 or 1.6 mM rutin; IVIG was treated with either 0.05 or 0.1 J/cm2 UVC in the presence of 0.5 or 1.0 mM rutin. Our results show that > or = 10(6.9) ID of EMCV and PPV were inactivated under each of the conditions studied except the treatment of albumin with 0.1 J/cm2 UVC in the presence of 1.6 mM rutin where 10(4.3) ID of EMCV and > or = 10(6.9) ID of PPV were killed. It appears that the sensitivity of PPV to UVC exceeds that of EMCV and that virus kill with UVC is higher in IVIG than in albumin. In the absence of rutin, UVC increased the extent of aggregation of both albumin and IVIG by two- to three-fold. With rutin present, the increase in albumin aggregation was reduced, and it was virtually eliminated by subsequent processing on Sephacryl S-200, a step in the existing procedure designed to remove aggregates. The increase in aggregation of IVIG appeared to be eliminated on inclusion of either 0.5 mM or 1 mM rutin. We conclude that both albumin and IVIG can be treated with UVC to inactivate > or = 10(6) ID of nonenveloped viruses. The inclusion of rutin during treatment helps protect against protein aggregation.
authors.affiliation: V.I. Technologies, Inc. (VITEX), New York, NY 10032, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chin
authors.forename: R
authors.initials: R
authors.lastname: Jin
authors.forename: X L
authors.initials: XL
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Hamman
authors.forename: G
authors.initials: G
authors.lastname: Marx
authors.forename: X
authors.initials: X
authors.lastname: Mou
authors.forename: I
authors.initials: I
authors.lastname: Andersson
authors.forename: L O
authors.initials: LO
authors.lastname: Lindquist
authors.forename: B
authors.initials: B
authors.lastname: Horowitz
mesh_terms: D001798:Blood Proteins / Q000528:radiation effects*; D017848:Blood-Borne Pathogens / Q000528:radiation effects*; D006507:Hepatovirus / Q000528:radiation effects*; D006801:Humans; D010321:Parvoviridae / Q000528:radiation effects*; D014466:Ultraviolet Rays
chemical_list: D001798:Blood Proteins